Literature DB >> 7963690

Development of ribozymes for gene therapy.

S M Sullivan1.   

Abstract

Ribozymes are a class of RNA molecules that can perform catalytically in the absence of protein. Specifically, they can hybridize to and cleave target RNA molecules independent of cellular proteins. The cleaved target RNA can not be translated thereby preventing synthesis of a specific protein. The therapeutic application is to target the ribozyme to the mRNA of a key protein or proteins involved in maintaining a disease state resulting in a cure. The ribozymes can be chemically synthesized and delivered to cells or they can be expressed from an expression vector following either permanent or transient transfection. Therapeutic applications of ribozymes have been in the areas of AIDS and cancer. The following article describes the ribozymes in more detail with respect to optimizing the design to obtain the maximal cleavage rate, identifying cleavage sites within the target RNA and delivering the ribozymes to cells of interest both in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7963690     DOI: 10.1038/jid.1994.15

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  4 in total

Review 1.  RNA structure and the regulation of gene expression.

Authors:  P Klaff; D Riesner; G Steger
Journal:  Plant Mol Biol       Date:  1996-10       Impact factor: 4.076

2.  Adenovirus-mediated expression of ribozymes in mice.

Authors:  A Lieber; M A Kay
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

3.  Elimination of hepatitis C virus RNA in infected human hepatocytes by adenovirus-mediated expression of ribozymes.

Authors:  A Lieber; C Y He; S J Polyak; D R Gretch; D Barr; M A Kay
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

Review 4.  RNA-based therapeutics: an overview and prospectus.

Authors:  Yiran Zhu; Liyuan Zhu; Xian Wang; Hongchuan Jin
Journal:  Cell Death Dis       Date:  2022-07-23       Impact factor: 9.685

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.